UK markets open in 1 hour 3 minutes
  • NIKKEI 225

    27,686.40
    -199.47 (-0.72%)
     
  • HANG SENG

    19,281.82
    -159.36 (-0.82%)
     
  • CRUDE OIL

    74.42
    +0.17 (+0.23%)
     
  • GOLD FUTURES

    1,784.30
    +1.90 (+0.11%)
     
  • DOW

    33,596.34
    -350.76 (-1.03%)
     
  • BTC-GBP

    13,994.76
    -117.97 (-0.84%)
     
  • CMC Crypto 200

    399.87
    -1.93 (-0.48%)
     
  • ^IXIC

    11,014.89
    -225.05 (-2.00%)
     
  • ^FTAS

    4,114.48
    -28.73 (-0.69%)
     

mRNA Vaccines and RNAi Therapeutics Market Report 2022: Target Specialty and Selectivity of Treatment to Further Propel Growth

Company Logo
Company Logo

Dublin, Oct. 31, 2022 (GLOBE NEWSWIRE) -- The "mRNA Vaccines and RNAi Therapeutics Market By Disease Type, By Route of administration, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

The single protein-coding gene known as messenger ribonucleic acid (mRNA) is located in the genome and provides the basis for how cells make proteins. Mammalian cells are used in the laboratory to create mRNA vaccines and treatments, which have positive immunological properties. Some of the most common types of vaccines and therapies include non-replicating, in vivo self-replicating, self-amplifying, and in-vitro dendritic cell non-replicating mRNA. They are administered intravenously to trigger the immune system's virus-detection mechanisms and trigger the production of viral antigen proteins by the cells. The body's immunity is strengthened through enhancing B- and T-cell responses.

The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects.

In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.

The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.

  • The market research is offered along with information related to key drivers, restraints, and opportunities.

  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

  • In-depth analysis of the mRNA vaccines and RNAi therapeutics market segmentation assists to determine the prevailing market opportunities.

  • Major countries in each region are mapped according to their revenue contribution to the global market.

  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

  • The report includes the analysis of the regional as well as global mRNA vaccines and RNAi therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments
By Disease Type

  • Hereditary transthyretin-mediated amyloidosis genetic

  • Acute hepatic porphyria

  • Primary hyperoxaluria type 1

  • Atherosclerotic cardiovascular disease

By Route of administration

  • IV infusion

  • Subcutaneous

By End user

  • Research Institutes

  • Hospitals and clinics

By Region

  • North America

  • U.S.

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Spain

  • Rest of Europe

  • Asia-Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • LAMEA

  • Brazil

  • Saudi Arabia

  • South Africa

  • Rest of LAMEA

Key Market Players

  • Alnylam Pharmaceuticals

  • BioNTech AG

  • Curevac AG

  • Etherna Immunotherapies

  • Ethris GMBH

  • IN-CELL-ART

  • Moderna Therapeutics

  • Sangamo Therapeutics, Inc.

  • Sanofi AG

  • SCM Life Sciences (Argos Therapeutics, Inc. )

  • Sarepta Therapeutics

  • Arcturus Therapeutics

  • Ionis Pharmaceuticals, Inc

  • Nutcracker

  • Tiba Biotech

Key Topics Covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE

CHAPTER 5: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER

CHAPTER 7: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

For more information about this report visit https://www.researchandmarkets.com/r/ey5ssw

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900